DGX · Insider Trading
Quest Diagnostics Inc.
Every open-market purchase and sale reported by DGX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Timothy C Wentworth | Director | A | +135 deriv. | — |
| 2026-09-03 | J. E. Davis | CEO and President | Sell | −10,000 | −$2.43M |
| 2026-08-31 | Michael E Prevoznik | SVP & General Counsel | MIXED | −1,000 | −$2.97M |
| 2026-07-29 | Mark E Delaney | SVP & Chief Commercial Officer | Sell | −1,600 | −$376.29K |
| 2026-07-27 | Sam Samad | Executive Vice President & CFO | A | +102 | +$21.09K |
| 2026-07-27 | Mark E Delaney | SVP & Chief Commercial Officer | L | +34 | +$7.03K |
| 2026-07-27 | Robert B Carter | Director | L | +11 | +$2.27K |
| 2026-07-27 | Patrick Plewman | SVP for Diagnostic Services | L | +46 | +$9.51K |
| 2026-07-27 | Vicky B Gregg | Director | A | +72 | +$14.89K |
| 2026-07-27 | Wright Lassiter III | Director | L | +6 | +$1.24K |
| 2026-07-27 | Timothy L Main | Director | L | +21 | +$4.34K |
| 2026-07-27 | Karthik Kuppusamy | SVP, Clinical Solutions | L | +37 | +$7.65K |
| 2026-07-02 | Timothy C Wentworth | Director | A | +144 deriv. | — |
| 2026-06-08 | Karthik Kuppusamy | SVP, Clinical Solutions | MIXED | — | −$617.40K |
| 2026-06-02 | J. E. Davis | CEO and President | Sell | −10,000 | −$1.94M |
| 2026-05-21 | Gary M Pfeiffer | Director | A | +1,142 | — |
| 2026-05-21 | Denise M Morrison | Director | A | +1,142 | — |
| 2026-05-21 | Wright Lassiter III | Director | A | +1,142 | — |
| 2026-05-21 | Timothy M Ring | Director | A | +1,142 | — |
| 2026-05-21 | Tracey Doi | Director | A | +1,142 | — |
| 2026-05-21 | Timothy C Wentworth | Director | A | +1,142 | — |
| 2026-05-21 | Timothy L Main | Director | A | +1,142 | — |
| 2026-05-21 | Luis Diaz | Director | A | +1,142 | — |
| 2026-05-21 | Vicky B Gregg | Director | A | +1,142 | — |
| 2026-05-21 | Robert B Carter | Director | A | +1,142 | — |
| 2026-04-24 | Mark E Delaney | SVP & Chief Commercial Officer | L | +37 | +$7.20K |
| 2026-04-24 | Karthik Kuppusamy | SVP, Clinical Solutions | L | +39 | +$7.59K |
| 2026-04-24 | Wright Lassiter III | Director | L | +6 | +$1.17K |
| 2026-04-24 | Robert B Carter | Director | L | +7 | +$1.36K |
| 2026-04-24 | Vicky B Gregg | Director | A | +68 | +$13.24K |
| 2026-04-24 | Patrick Plewman | SVP for Diagnostic Services | L | +49 | +$9.54K |
| 2026-04-24 | Sam Samad | Executive Vice President & CFO | A | +108 | +$21.03K |
| 2026-04-02 | Timothy C Wentworth | Director | A | +198 deriv. | — |
| 2026-03-11 | Timothy C Wentworth | Director | A | +215 | — |
| 2026-03-06 | Karthik Kuppusamy | SVP, Clinical Solutions | MIXED | +3,572 | +$731.76K |
| 2026-03-06 | Michael J Deppe | SVP, Corp. Controller & CAO | MIXED | +723 | +$148.11K |
| 2026-03-06 | Patrick Plewman | SVP for Diagnostic Services | MIXED | — | −$3.85K |
| 2026-03-06 | J. E. Davis | CEO and President | MIXED | +25,238 | +$5.17M |
| 2026-03-06 | Michael E Prevoznik | SVP & General Counsel | MIXED | — | −$5.24K |
| 2026-03-06 | Mark E Delaney | SVP & Chief Commercial Officer | MIXED | +3,356 | +$687.51K |
| 2026-03-06 | Catherine T. Doherty | EVP, Regional Businesses | MIXED | — | −$7.50K |
| 2026-03-06 | Sam Samad | Executive Vice President & CFO | MIXED | +6,227 | +$1.28M |
| 2026-03-04 | Michael J Deppe | SVP, Corp. Controller & CAO | F | −88 | −$18.03K |
| 2026-03-04 | Mark E Delaney | SVP & Chief Commercial Officer | F | −188 | −$38.51K |
| 2026-03-04 | Karthik Kuppusamy | SVP, Clinical Solutions | F | −205 | −$42.00K |
| 2026-03-04 | Patrick Plewman | SVP for Diagnostic Services | MIXED | −640 | −$132.29K |
| 2026-03-04 | J. E. Davis | CEO and President | MIXED | −12,968 | −$2.73M |
| 2026-03-04 | Michael E Prevoznik | SVP & General Counsel | MIXED | −814 | −$168.27K |
| 2026-03-04 | Sam Samad | Executive Vice President & CFO | F | −869 | −$178.02K |
| 2026-03-04 | Catherine T. Doherty | EVP, Regional Businesses | MIXED | −1,280 | −$264.03K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| J. E. Davis | CEO and President | 122,423 | $29.80M |
| Catherine T. Doherty | EVP, Regional Businesses | 71,624 | $17.44M |
| Michael E Prevoznik | SVP & General Counsel | 43,767 | $10.65M |
| Michael J Deppe | SVP, Corp. Controller & CAO | 36,652 | $8.92M |
| Sam Samad | Executive Vice President & CFO | 33,478 | $8.15M |
| Timothy M Ring | Director | 31,140 | $7.58M |
| Gary M Pfeiffer | Director | 31,005 | $7.55M |
| Timothy L Main | Director | 27,460 | $6.68M |
| Vicky B Gregg | Director | 18,386 | $4.48M |
| Patrick Plewman | SVP for Diagnostic Services | 15,293 | $3.72M |
| Karthik Kuppusamy | SVP, Clinical Solutions | 13,915 | $3.39M |
| Denise M Morrison | Director | 11,929 | $2.90M |
| Mark E Delaney | SVP & Chief Commercial Officer | 10,335 | $2.52M |
| Wright Lassiter III | Director | 10,323 | $2.51M |
| Tracey Doi | Director | 7,748 | $1.89M |
| Luis Diaz | Director | 5,196 | $1.26M |
| Robert B Carter | Director | 3,864 | $940.61K |
| Timothy C Wentworth | Director | 1,358 | $330.58K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the DGX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.